A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours
Le Tourneau, Christophe, Delord, Jean-Pierre, Kotecki, Nuria, Borcoman, Edith, Gomez-Roca, Carlos, Hescot, Ségolène, Jungels, Christiane, Vincent-Salomon, Anne, Cockenpot, Vincent, Eberst, Lauriane,Journal:
British Journal of Cancer
DOI:
10.1038/s41416-020-01028-8
Date:
August, 2020
File:
PDF, 702 KB
2020
File converter
More search results
More benefits 
